CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

CagriSema expected to yield more weight loss Novo Nordisk's head of development, Martin Holst Lange, told Reuters that CagriSema could deliver 25 percent weight loss, compared to Wegovy's 15 percent.

CagriSema patients lost more weight than those taking either component alone: 20.4% for the combination vs 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo.

In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and ...

Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with ...

CagriSema was said to also have similar side effects as other GLP-1 drugs on the market – effects which include gastrointestinal discomfort. However, they diminished over time. Despite these ...

The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7 ...

Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently ...

At week 68, participants in REDEFINE 1 had lost a mean 20.4% of their body weight with CagriSema vs 14.9% with semaglutide, 11.5% with cagrilintide, and 3.0% with placebo.